172 related articles for article (PubMed ID: 37675271)
1. Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies.
Li R; Shen M; Ong JJ; Cui F; Hu W; Chan P; Zou Z; Su S; Liu H; Zhang L; Seto WK; Wong WCW
JHEP Rep; 2023 Oct; 5(10):100833. PubMed ID: 37675271
[TBL] [Abstract][Full Text] [Related]
2. Modelling the prevalence of hepatitis B towards eliminating it as a major public health threat in China.
Liu W; Zhuang T; Xia R; Zou Z; Zhang L; Shen M; Zhuang G
BMC Public Health; 2022 Jun; 22(1):1179. PubMed ID: 35698098
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation.
Zhang S; Wang C; Liu B; Lu QB; Shang J; Zhou Y; Jia J; Xu X; Rao H; Han B; Zhao T; Chen L; Xie M; Cui J; Du J; Zeng J; Huang N; Liu Y; Zhang L; Zhuang H; Cui F
Lancet Reg Health West Pac; 2023 Jun; 35():100738. PubMed ID: 37424693
[TBL] [Abstract][Full Text] [Related]
4. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of hepatitis B elimination in high-income countries with ongoing immigration.
Tian F; Feld JJ; Feng Z; Sander B; Wong WWL
J Hepatol; 2022 Oct; 77(4):947-956. PubMed ID: 35483535
[TBL] [Abstract][Full Text] [Related]
6. Modeling the Impacts of Prevention and Treatment Interventions on Hepatitis C Among People Who Inject Drugs in China.
Fang K; Wang HL; Lin Y; Li S; Wu J
Infect Dis Ther; 2023 Apr; 12(4):1043-1055. PubMed ID: 36894824
[TBL] [Abstract][Full Text] [Related]
7. Countdown to 2030: eliminating hepatitis B disease, China.
Liu J; Liang W; Jing W; Liu M
Bull World Health Organ; 2019 Mar; 97(3):230-238. PubMed ID: 30992636
[TBL] [Abstract][Full Text] [Related]
8. A tool to measure the economic impact of Hepatitis B elimination: A case study in Saudi Arabia.
Sanai FM; Alghamdi M; Dugan E; Alalwan A; Al-Hamoudi W; Abaalkhail F; AlMasri N; Razavi-Shearer D; Razavi H; Schmelzer J; Alfaleh FZ
J Infect Public Health; 2020 Nov; 13(11):1715-1723. PubMed ID: 32988769
[TBL] [Abstract][Full Text] [Related]
9. Impact and Cost-Effectiveness of Biomedical Interventions on Adult Hepatitis B Elimination in China: A Mathematical Modelling Study.
Wang X; Du Z; Wang Y; Wang J; Huang S; Wang Y; Gu J; Deng W; Gilmour S; Li J; Hao Y
J Epidemiol Glob Health; 2023 Sep; 13(3):517-527. PubMed ID: 37349664
[TBL] [Abstract][Full Text] [Related]
10. Impact of the national hepatitis B immunization program in China: a modeling study.
Liu Z; Li M; Hutton DW; Wagner AL; Yao Y; Zhu W; Cao L; Tang S; Pan J; Wang Y; Zhao Q; Ren H; Wang Y; Wang W
Infect Dis Poverty; 2022 Oct; 11(1):106. PubMed ID: 36221140
[TBL] [Abstract][Full Text] [Related]
11. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
GBD 2019 Hepatitis B Collaborators
Lancet Gastroenterol Hepatol; 2022 Sep; 7(9):796-829. PubMed ID: 35738290
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Progress towards elimination of mother-to-child transmission of hepatitis B virus infection in China: a modelling analysis.
Hui Z; Nayagam S; Chan P; Fuzhen W; Thursz M; Zundong Y; Ning M; Xiaojin S; Cui F; Guomin Z; Hallett TB
Bull World Health Organ; 2021 Jan; 99(1):10-18. PubMed ID: 33658732
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.
Su S; Wong WC; Zou Z; Cheng DD; Ong JJ; Chan P; Ji F; Yuen MF; Zhuang G; Seto WK; Zhang L
Lancet Glob Health; 2022 Feb; 10(2):e278-e287. PubMed ID: 35063115
[TBL] [Abstract][Full Text] [Related]
15. Disease burden of chronic hepatitis B and complications in China from 2006 to 2050: an individual-based modeling study.
Zheng Y; Wu J; Ding C; Xu K; Yang S; Li L
Virol J; 2020 Aug; 17(1):132. PubMed ID: 32859216
[TBL] [Abstract][Full Text] [Related]
16. Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030.
Howell J; Pedrana A; Cowie BC; Doyle J; Getahun A; Ward J; Gane E; Cunningham C; Wallace J; Lee A; Malani J; Thompson A; Hellard ME
J Gastroenterol Hepatol; 2019 Jan; 34(1):40-48. PubMed ID: 30151932
[TBL] [Abstract][Full Text] [Related]
17. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.
Polaris Observatory Collaborators
Lancet Gastroenterol Hepatol; 2023 Oct; 8(10):879-907. PubMed ID: 37517414
[TBL] [Abstract][Full Text] [Related]
18. Chronic hepatitis B virus infection in Asian countries.
Merican I; Guan R; Amarapuka D; Alexander MJ; Chutaputti A; Chien RN; Hasnian SS; Leung N; Lesmana L; Phiet PH; Sjalfoellah Noer HM; Sollano J; Sun HS; Xu DZ
J Gastroenterol Hepatol; 2000 Dec; 15(12):1356-61. PubMed ID: 11197043
[TBL] [Abstract][Full Text] [Related]
19. The current and future burden of hepatitis B in Switzerland: a modelling study.
Negro F; Müllhaupt B; Semela D; Blach S; Bruggmann P; De Gottardi A; Dufour JF; Fraga M; Galante A; Razavi H; Vieira Barbosa J; Razavi-Shearer D
Swiss Med Wkly; 2023 Jun; 153():40086. PubMed ID: 37410921
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
